Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Norman Wolmark, MD, of Allegheny General Hospital, discuss the landmark trials of NSABP that have led to profound changes in breast cancer treatment. (Abstract ML-1)
Andrew Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Eric P. Winer, MD, of the Dana-Farber Cancer Institute, discuss the results of this study that s...
Gunter von Minckwitz, MD, of the German Breast Group, discusses data from this phase II trial investigating the addition of carboplatin to neoadjuvant therapy for triple-negative a...
Michael Gnant, MD, of the Medical University of Vienna, discusses a study in which denosumab was added to adjuvant aromatase inhibitor therapy to improve disease-free survival in p...
Lisa A. Carey, MD, of the University of North Carolina, and Sibylle Loibl, MD, PhD, of the German Breast Group, discuss new data on palbociclib, new immunotherapy,...
Sherene Loi, MD, of Peter MacCallum Cancer Centre, discusses a pooled individual patient data analysis of stromal tumor-infiltrating lymphocytes in primary triple-negative breast c...
